Gene therapy company AavantiBio and Catalent, technologies, development, and manufacturing solutions service, have partnered to support the development and manufacturing of AavantiBio’s gene therapies, including Friedreich’s Ataxia (FA).
Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the US and Europe.
“We look forward to working with Catalent on the development of our differentiated pipeline of innovative gene transfer therapies, focused initially on our FA program,” said Bo Cumbo, President and Chief Executive Officer of AavantiBio. “This partnership highlights the importance of prioritising chemistry, manufacturing and controls as a foundational element of the company. We believe this approach will position AavantiBio for long-term success as we begin to advance therapies to transform the lives of patients with FA and other rare diseases.”